Cefotaxime
Claforan (cefotaxime) is a small molecule pharmaceutical. Cefotaxime was first approved as Claforan on 1982-01-01. It is used to treat acinetobacter infections, bacterial infections, bacterial meningitis, bacterial pneumonia, and bacterial skin diseases amongst others in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Cefotaxime sodium
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| CEFOTAXIME AND DEXTROSE 2.4% IN PLASTIC CONTAINER | B. Braun Medical | N-050792 DISCN | 2004-07-29 | 1 products |
| CEFOTAXIME AND DEXTROSE 3.9% IN PLASTIC CONTAINER | B. Braun Medical | N-050792 DISCN | 2004-07-29 | 1 products |
| CLAFORAN | Validus Pharmaceuticals | N-050547 DISCN | 1982-01-01 | 4 products, RLD |
| CLAFORAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER | Validus Pharmaceuticals | N-050596 DISCN | 1985-05-20 | 1 products |
| CLAFORAN IN DEXTROSE 5% IN PLASTIC CONTAINER | Validus Pharmaceuticals | N-050596 DISCN | 1985-05-20 | 1 products |
| CLAFORAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER | Validus Pharmaceuticals | N-050596 DISCN | 1985-05-20 | 1 products |
| CLAFORAN IN DEXTROSE 5% IN PLASTIC CONTAINER | Validus Pharmaceuticals | N-050596 DISCN | 1985-05-20 | 1 products |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| cefotaxime | unapproved drug for use in drug shortage | 2024-12-12 |
Indications
FDA
EMA
Show 14 more
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| J0698 | Injection, cefotaxime sodium, per gm |
Clinical
Clinical Trials
234 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Infections | D007239 | EFO_0000544 | — | 4 | 10 | 8 | 9 | 14 | 44 |
| Pneumonia | D011014 | EFO_0003106 | J18 | 1 | 6 | 13 | 12 | 7 | 36 |
| Communicable diseases | D003141 | — | — | 3 | 5 | 7 | 7 | 8 | 30 |
| Gonorrhea | D006069 | DOID_7551 | A54 | 4 | 3 | 6 | 3 | — | 16 |
| Sepsis | D018805 | EFO_0001420 | A41.9 | — | — | 5 | 4 | 5 | 14 |
| Appendicitis | D001064 | EFO_0007149 | K37 | 1 | 3 | — | 3 | 6 | 13 |
| Urinary tract infections | D014552 | EFO_0003103 | N39.0 | 1 | 1 | 3 | 4 | 1 | 10 |
| Bacterial pneumonia | D018410 | EFO_1001272 | J15.9 | — | 4 | 6 | 1 | — | 9 |
| Respiratory tract infections | D012141 | — | J06.9 | — | — | 1 | 1 | 7 | 9 |
| Surgical wound infection | D013530 | — | — | 1 | 2 | 3 | 2 | 1 | 8 |
Show 64 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Bacterial infections | D001424 | — | A49 | 1 | — | 1 | — | 5 | 7 |
| Lyme disease | D008193 | — | A69.2 | 1 | 1 | 2 | — | 1 | 5 |
| Covid-19 | D000086382 | — | U07.1 | 1 | 1 | 2 | — | 1 | 4 |
| Hiv infections | D015658 | EFO_0000764 | B20 | — | 1 | 2 | — | 2 | 4 |
| Antibiotic prophylaxis | D019072 | — | — | — | 1 | 2 | — | 1 | 4 |
| Malnutrition | D044342 | EFO_0008572 | E40-E46 | — | 2 | 2 | — | — | 3 |
| Healthy volunteers/patients | — | — | — | 2 | 2 | 1 | — | — | 3 |
| Post-lyme disease syndrome | D000077342 | — | — | 1 | — | 2 | — | — | 3 |
| Lung diseases | D008171 | EFO_0003818 | J98.4 | — | 2 | 1 | — | — | 2 |
| Community-acquired infections | D017714 | — | — | — | 1 | 2 | — | — | 2 |
Show 31 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Endometritis | D004716 | EFO_1001312 | — | — | 2 | — | — | 1 | 3 |
| Coinfection | D060085 | — | — | — | 1 | — | — | 2 | 3 |
| Chlamydia infections | D002690 | EFO_0007205 | A74.9 | — | 1 | — | — | 1 | 2 |
| Bipolar disorder | D001714 | EFO_0000289 | F30.9 | — | 1 | — | — | 1 | 2 |
| Ulcerative colitis | D003093 | EFO_0000729 | K51 | — | 1 | — | — | — | 1 |
| Inflammatory bowel diseases | D015212 | EFO_0003767 | — | — | 1 | — | — | — | 1 |
| Colitis | D003092 | EFO_0003872 | K52.9 | — | 1 | — | — | — | 1 |
| Ulcer | D014456 | MPATH_579 | — | — | 1 | — | — | — | 1 |
| Subacute bacterial endocarditis | D004698 | EFO_1001193 | — | — | 1 | — | — | — | 1 |
| Parkinson disease | D010300 | EFO_0002508 | G20 | — | 1 | — | — | — | 1 |
Show 29 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | — | C80 | 4 | — | — | — | — | 4 |
| Neuroblastoma | D009447 | EFO_0000621 | — | 2 | — | — | — | — | 2 |
| Drug-related side effects and adverse reactions | D064420 | — | T88.7 | 1 | — | — | — | — | 1 |
| Focus groups | D017144 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pharmacokinetics | D010599 | — | — | — | — | — | — | 2 | 2 |
| Hiv seropositivity | D006679 | — | — | — | — | — | — | 2 | 2 |
| Varicose veins | D014648 | — | I83.90 | — | — | — | — | 2 | 2 |
| Erectile dysfunction | D007172 | EFO_0004234 | F52.21 | — | — | — | — | 1 | 1 |
| Drug monitoring | D016903 | — | — | — | — | — | — | 1 | 1 |
| Jaundice | D007565 | — | R17 | — | — | — | — | 1 | 1 |
| Propionibacterium acnes | D011425 | NCBITaxon_1747 | — | — | — | — | — | 1 | 1 |
| Cellulitis | D002481 | EFO_0003035 | L03.90 | — | — | — | — | 1 | 1 |
| Aseptic meningitis | D008582 | EFO_1000823 | G03.0 | — | — | — | — | 1 | 1 |
| Benign migratory glossitis | D005929 | EFO_0007283 | K14.1 | — | — | — | — | 1 | 1 |
Show 40 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Cefotaxime |
| INN | cefotaxime |
| Description | (6R,7R)-3-(acetyloxymethyl)-7-[[2-(2-amino-4-thiazolyl)-2-methoxyimino-1-oxoethyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid is a cephalosporin. |
| Classification | Small molecule |
| Drug class | cephalosporins |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=C(COC(C)=O)CS[C@H]12)c1csc(N)n1 |
Identifiers
| PDB | — |
| CAS-ID | 63527-52-6 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1730 |
| ChEBI ID | 204928 |
| PubChem CID | 5479527 |
| DrugBank | DB00493 |
| UNII ID | N2GI8B1GK7 (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 35,135 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
3,868 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use